leisure time -WSS

leisure time

author：comprehensive 2025-09-06 04:13:17 - browse：974

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Moderna says combo Covid

WSS

Federal weight loss drug coverage is 30 years out of date

3 trends to watch in health tech's hiring outlook for 2024

UCB departs biotech trade group BIO

New weight loss drugs work. But how can they best be used?

New weight loss drugs work. But how can they best be used?

Federal weight loss drug coverage is 30 years out of date

knowledge

leisure time

entertainment

Apple is now the first public company to be valued at $3 trillion

Antibiotic resistance and the global rise in human conflict

Moonlake's readout produced a cash windfall. Risks remain

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Walensky prepares to leave CDC — and Congress — behind

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Feng Zhang CRISPR delivery startup lays off quarter of staff

Dobbs anniversary: the lost opportunity of abortion as health care

Goldman Sachs launches $650M fund for life science investments

hotspot

Cheap, fast test for Zika and dengue could cost just $1

How faith leaders like me can help address America's obesity epidemic

New report analyzes digital physical therapy solutions' effectiveness

Health care court cases: Humana, Sutter, Novant

Cheap, fast test for Zika and dengue could cost just $1

Report captures long Covid’s disabling effects and policy challenges

Wikipedia

hotspot

hotspot

focus